🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Canada / NCT06458322
Recruiting Observational

Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME)

NCT06458322 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2022-07-01
Last updated
2026-02-23

Condition(s) studied

Chronic Kidney Diseases

Investigational drug(s) / intervention(s)

Home dialysis or In-Center dialysis

Home dialysis or In-Center dialysis: Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)

Study summary

The goal of this study is to evaluate quality of life (QoL) and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis.

The main questions it aims to answer are:

1. What is the trajectory of QoL in patients transitioning from advanced CKD to dialysis (up to 12 months after initiation) and how does these changes differ for patients oriented towards home dialysis and in-center hemodialysis?
2. Is the development of frailty after dialysis initiation less likely in patient pursuing home dialysis?
3. What is the variation in other PROMs and health outcomes (fatigue, anxiety \& depression, general assessment, cognitive function) form advanced CKD to the first 12 months after dialysis initiation?
4. What are the predictors of severe decline in QoL, frailty and other important health outcomes (fatigue, cognition, anxiety \& depression) during CKD G5 follow-up and after 12 months post dialysis initiation?

Participants will be ask to:

* Answer some questions and complete questionnaires each 3 months;
* Do a a grip test and a walking test each 6 months to evaluate their frailty;

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients followed in advanced CKD clinic; * eGFR ≤12 mL/min/1.73m2 96; * Understand English or French. Exclusion Criteria: * Orientation toward conservative treatment; * Planned kidney transplantation \< 6 months; * Unable to provide consent due to severe cognitive or psychiatric disease; * Previous treatment with dialysis \> 3 month; * Life expectancy \< 6 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hôpital Maisonneuve-Rosemont Montreal Quebec Recruiting

More Ciusss de L'Est de l'Île de Montréal trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06458322 on ClinicalTrials.gov ↗ ← All trials in Canada